Innovis Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Innovis Asset Management's VRTX Position: Q3 2023 in Review
Innovis Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.15% in Q3 2023, selling an estimated $11.9K and leaving 22,505 shares worth $7.83M. The position accounts for 3.01% of the portfolio, ranked #5.
Innovis Asset Management first reported a position in VRTX in Q4 2022 and has held it in 4 quarters since. The position peaked at $7.93M in Q2 2023. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.
- Innovis Asset Management held 22,505 shares of Vertex Pharmaceuticals worth $7.83M as of Q3 2023.
- Innovis Asset Management sold 34 Vertex Pharmaceuticals shares in Q3 2023, an estimated $11.9K.
- Vertex Pharmaceuticals made up 3.01% of Innovis Asset Management's portfolio in Q3 2023, its #5 holding.
- Innovis Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 4 quarters since.
- Innovis Asset Management's Vertex Pharmaceuticals position peaked at $7.93M in Q2 2023.
- 1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.
Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.